Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin.

@article{Yuste2005ActivationOE,
  title={Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin.},
  author={Laura Cano Yuste and Juan Carlos Montero and Azucena Espar{\'i}s-Ogando and Atanasio Pandiella},
  journal={Cancer research},
  year={2005},
  volume={65 15},
  pages={
          6801-10
        }
}
The ligands of the epidermal growth factor family and their receptors, the ErbB proteins, have been linked to the development of different types of cancer. Particular attention has focused on ErbB2, whose activation may occur by receptor overexpression or by ligand-induced oligomerization with other ErbB receptors. Whether these two modes of ErbB2 activation cause the same biological responses is unknown. Here, we uncovered important differences in the signaling, proliferation rates, and the… CONTINUE READING

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 41 CITATIONS

HER receptor-mediated dynamic signalling in breast cancer cells

VIEW 5 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 38 REFERENCES

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2003
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation.

  • Proceedings of the National Academy of Sciences of the United States of America
  • 2003
VIEW 1 EXCERPT